- Home
- NRXP vs XGN Comparison
NRXP vs XGN Comparison
Compare NRXP & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRXP | XGN |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United States | United States |
| Employees | 29 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.2M | 110.4M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | NRXP | XGN |
|---|---|---|
| Price | $3.73 | $4.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $38.25 | $8.86 |
| AVG Volume (30 Days) | ★ 1.4M | 295.9K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2,547.84 | $8.12 |
| Revenue Next Year | $1,591.73 | $13.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.65 | $2.59 |
| 52 Week High | $5.06 | $12.23 |
Technical Indicators
Market Signals| Indicator | NRXP | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 48.47 | 55.13 |
| Support Level | $3.45 | $4.11 |
| Resistance Level | $3.84 | $4.85 |
| Average True Range (ATR) | 0.32 | 0.34 |
| MACD | -0.09 | -0.04 |
| Stochastic Oscillator | 45.00 | 52.22 |
Price Performance
Historical ComparisonAbout NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About XGN Exagen Inc.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.